Now Available: Psoriasis: Update Bulletin [April 2016]

Gain new KOL insights on the latest events happening in plaque psoriasis. Topics covered include opinions regarding several biosimilar anti-TNFs, including Samsung Bioepis' Benepali (etanercept) and Flixabi (infliximab); US approval and EU positive opinion for Eli Lilly's Taltz (ixekizumab), as well as views on Boehringer Ingelheim's/AbbVie's risankizumab (BI 655066), an anti-IL-23 monoclonal antibody, undergoing Phase III trials as a potential treatment for psoriasis.

* How do KOLs view Benepali's label restrictions?
* Will the availability of two biosimilar infliximab products result in increased biosimilar infliximab adoption in the psoriasis setting?
* How do KOLs rate Merck KGaA's Phase III trial of MSB11022, a proposed biosimilar adalimumab?
* How do KOLs view Eli Lilly's Taltz (ixekizumab), and where in the treatment paradigm will such a product be used?
* What are KOLs' opinions regarding risankizumab (BI 655066) and where would it be positioned in the treatment paradigm?

Full Report Details at
- http://www.fastmr.com/prod/1180407_psoriasis_update_bulletin.aspx?afid=301

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Psoriasis: Update Bulletin [January 2016]
- Targeted Therapies In Asthma: Update Bulletin [April 2016]
- Malignant Melanoma: Update Bulletin [April 2016]
- Type 2 Diabetes Mellitus: Update Bulletin [April 2016]
- NSCLC: Update Bulletin [April 2016]